Traws Pharma, Inc. (TRAW) intrinsic value & 10-year financials
Traws Pharma, Inc. (TRAW) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 7.3% a year to $2.8M, with an average return on invested capital of 166.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.37
- Market cap
- $3.1M
- Revenue (FY2025)
- $2.8M
- Revenue growth (10-yr CAGR)
- -7.3%
- ROIC (10-yr avg)
- 166.3%
- Free cash flow (FY2025)
- -$20.8M
TRAW 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.8M | $9.2M | $0.82 | -$20.8M | -640.7% | -56.9% |
| FY2024 | $226.0K | -$166.5M | -$35.21 | -$33.4M | -62997.3% | 1589.1% |
| FY2023 | $226.0K | -$18.9M | -$0.90 | -$17.9M | -8981.4% | -97.2% |
| FY2022 | $226.0K | -$19.0M | -$0.91 | — | -8684.5% | -51.0% |
| FY2021 | $226.0K | -$16.2M | -$0.96 | — | -7299.1% | -61.8% |
| FY2020 | $231.0K | -$25.2M | -$2.17 | -$23.1M | -10819.5% | -281.6% |
| FY2019 | $2.2M | -$21.5M | — | -$20.9M | -994.0% | -255.9% |
| FY2018 | $1.2M | -$20.6M | — | — | -1895.9% | 734.2% |
| FY2017 | $787.0K | -$24.1M | — | — | -3270.3% | 696.2% |
| FY2016 | $5.5M | -$19.7M | — | — | -427.4% | -551.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Traws Pharma, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Traws Pharma, Inc. has historically struggled to out-earn its cost of capital, averaging just -24.8% ROIC.
Traws Pharma, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Traws Pharma, Inc. is modeled at -7.3% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-4.39 per share.